Celadon Partners SPV 24

Celadon Partners SPV 24 is a special purpose vehicle (SPV) managed by Celadon Partners, a Hong Kong-based private equity firm specializing in the healthcare, technology, and consumer sectors. The entity functions as a dedicated investment holding company used to manage specific equity positions in biotechnology and life science companies, primarily within the Greater China region. It is notably recognized as a significant Pre-IPO investor in ImmuneOnco Biopharmaceuticals, a clinical-stage company developing novel immuno-oncology therapies. As a financial vehicle, Celadon Partners SPV 24 does not directly conduct research and development or maintain an internal drug pipeline, but rather provides essential capital to support the growth of innovative healthcare firms. It represents a structured investment approach by its parent firm to gain targeted exposure to high-potential assets in the biopharmaceutical industry.